MRI and CT Simulation in the Evaluation of Tumor Response and Target Volume Definition for Esophageal or Esophagogastric Cancer Patients Undergoing Chemoradiotherapy

Esophagus Cancer Clinical Trial

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT02988921
• Other study ID #: 16-161/1240
• Status: Recruiting
• Phase: N/A
• Start date: October 2016
• Est. completion date: December 2026

Study information

• Verified date: November 2023
• Source: Cancer Institute and Hospital, Chinese Academy of Medical Sciences
• Contact: Xin Wang, MD
• Phone: +861013311583220
• Email: beryl_wx2000[@]163.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Magnetic resonance imaging (MRI) with functional features of diffusion weighted imaging (DWI) are advancing imaging technologies that have potential to overcome limitations of conventional staging methods, radiation treatment planning and the assessment of tumor response in esophageal or esophagogastric cancer. This study aimed to explore the value of MRI for the prediction of tumor response to chemoradiotherapy and accurate target volume delineation as compared to CT simulation for patients with unresectable or potentially resectable esophageal or esophagogastric cancer undergoing chemoradiotherapy. The average CT texture features are also extracted before and during treatment to establish a model to predict the prognosis or side effects (e.g. radiation pneumonitis or esophagitis) of patients.

Description:

1. Both DW-MRI and CT simulation will be performed before chemoradiotherapy and after 18-22 fractions. Also MRI will be performed after treatment. The investigators will contour based on the MRI image and compare this with the standard CT plan before and during treatment. 2. The predictive potential of initial tumor ADC, and change in ADC during and after treatment for tumor response will be assessed. 3. The average CT texture features not only in the present study but also of those who treated previously in our department (since 2014) will be extracted before and during chemoradiotherapy to establish a model to predict the prognosis of patients.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 300
• Est. completion date: December 2026
• Est. primary completion date: January 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Histologically confirmed squamous cell carcinoma, adenocarcinoma of the esophageal or esophagogastric junction
• Unresectable or potentially resectable tumor (cT3-4N0-1M0-M1a, according to AJCC 6th) based on standard primary staging by EUS and CT
• Age>18 years
• No distant metastasis other than supraclavicular lymph nodes
• No prior history of thoracic radiation or chemotherapy
• Patients must have normal organ and marrow function as defined below: Leukocytes:

greater than or equal to 3,500 G/L; Platelets: greater than or equal to 100,000/mm3 .Hemoglobin:greater than or equal to 10g/L .Total bilirubin: within normal institutional limits; AST/ALT: less than or equal to 1.5 times the upper limit; Creatinine within normal upper limits

• Informed consent

Exclusion Criteria:

• Contraindication for MRI scanning
• Patients with other cancer history except cervical carcinoma in situ and non-malignant melanoma skin cancer
• Pregnant or lactating females
• Contraindication for radiotherapy or chemotherapy

Related Conditions & MeSH terms

• Esophageal Neoplasms
• Esophagogastric Junction Cancer
• Esophagus Cancer

Intervention

Device:
• MRI and CT

Radiation:
• Ratiotherapy

Drug:
• Paclitaxel, platinum-based drug

Locations

Country	Name	City	State
China	Department of Radiation Oncology, Cancer Hospital, National Cancer Center, Chinese Academy of Medical Sciences (CAMS) and Peking Union Medical College (PUMC)	Beijing

Sponsors (1)

Lead Sponsor	Collaborator
Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Tumor response based on MRI and CT simulation		up to 8 weeks
Primary	Radiotherapy target volume assessment with pre- and post-chemoradiotherapy based on MRI and CT simulation		up to 8 weeks
Primary	Evaluation of tumor heterogeneity with IBEX software	Using the average CT images for texture extraction. Histogram, gradient, cooccurrence, gray-tone difference, and filtration-based techniques are used for texture feature extraction. Models incorporating texture features are established to compare to models incorporating clinical prognostic factors alone.	up to 8 weeks
Secondary	Overall survival		1 year
Secondary	Progress free survival		1 year
Secondary	Reduction in acute and late side effects based on modified RT treatment volumes with pre- and post-chemoradiotherapy based on MRI and CT simulation		1 year